First-timer resumes PBAC fight
Posted 22 February 2021 PM
After registering its first product in Australia this month, Kyowa Kirin has confirmed it will continue to pursue reimbursement for Poteligeo despite already being rejected twice by the PBAC.
Prior to the TGA's approval, the medicine had been knocked back at the PBAC's July meeting and November meeting in 2020 for two rare forms of lymphoma - mycosis fungoides and Sezary syndrome.
Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here